Opinion|Videos|April 10, 2025
Learnings From the VISIBLE Study in Skin of Color
Panelists discuss how despite limited but encouraging efficacy and safety data from studies like VISIBLE (guselkumab) and various subgroup analyses supporting biologic use across diverse skin tones, clinicians must still consider unique presentations and concerns when treating patients with skin of color, including postinflammatory hyperpigmentation, follicular presentation patterns, cultural perspectives on treatment, and historical underrepresentation in clinical trials, while emphasizing the importance of personalized discussions about treatment expectations and outcomes specific to different skin phototypes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Data, while limited, show that biologics are safe and effective treatment options across skin tones. How do you take these data into consideration when deciding on treatment for your patients with skin of color?
VISIBLE study—guselkumab- Various subgroup and post hoc analyses
Advertisement
Related to this article
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data
5